Mahanine mediated therapeutic inhibition of estrogen receptor-α and CDK4/6 expression, decipher the chemoprevention-signaling cascade in preclinical model of breast cancer

被引:3
|
作者
Samanta, Suman Kumar [1 ,2 ]
Choudhury, Paramita [2 ,3 ]
Kandimalla, Raghuram [2 ,4 ,5 ]
Aqil, Farrukh [4 ,6 ]
Moholkar, Disha N. [4 ,5 ]
Gupta, Ramesh C. [4 ,5 ]
Das, Momita [2 ]
Gogoi, Bhaskarjyoti [7 ]
Gogoi, Neelutpal [8 ]
Sarma, Partha Pratim [2 ]
Devi, Rajlakshmi [2 ]
Talukdar, Narayan C. [1 ]
机构
[1] Assam Down Town Univ, Fac Sci, Gauhati 781026, Assam, India
[2] Inst Adv Study Sci & Technol, Life Sci Div, Tradit & Modern Drug Discovery & Dis Diag Lab, Gauhati 781035, Assam, India
[3] Gauhati Univ, Dept Zool, Gauhati 781014, Assam, India
[4] Univ Louisville, Brown Canc Ctr, Louisville, KY 40202 USA
[5] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA
[6] Univ Louisville, Dept Med, Louisville, KY 40202 USA
[7] Assam Royal Global Univ, Dept Biotechnol, Gauhati 781035, Assam, India
[8] Dibrugarh Univ, Dept Pharmaceut Sci, Dibrugarh 786004, Assam, India
关键词
Murraya koenigii; Mahanine; Breast cancer; Chemoprevention; ER alpha antagonist; CDK4/6; inhibitor; LEPTIN; RESISTANCE; GROWTH; CELLS; RNA;
D O I
10.1016/j.jep.2023.117235
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Mahanine (MH), a naturally occurring carbazole alkaloid, isolated from Ayurvedic medicinal plant Murraya koenigii (L.) Spreng, has been shown to have various pharmacological properties, including its inhibitory activity against different breast cancers (BC) subtypes.Aim of the study: While MH triggers apoptosis in BC cells regardless of subtype, the specific mechanism of MH action is not fully understood. In this study, we show the effect of MH in preventing BC progression by inducing apoptosis in relation to estrogen receptor-alpha (ER alpha) and cell cycle regulatory proteins.Materials and methods: To assess the pharmacological activity in various in vitro and in vivo tests, isolated and pure MH was used. To conclude the study, cutting edged molecular biology techniques including Western blot analysis, enzyme-linked immunosorbent assay (ELISA), molecular simulation study, and other related software analysis were employed.Results: MH demonstrated dose dependent cell viability against drug sensitive (MCF-7 and MDA-MB-231) and paclitaxel resistant (MCF-7TR and MDA-MB-231TR) BC cells. MH also exhibited synergistic activity with tamoxifen (TAM) against estrogen receptor positive (ER+) BC cells by inhibiting ER alpha expression in MCF-7 cells and N-Methyl-N-nitrosourea (MNU)-induced mammary tumor in a dose-dependent manner while having no effect on vinculin expression. In addition, MH inhibited cell cycle regulatory genes namely CDK1/CDK4/CDK6/ CDC25A and neo-angiogenesis through downregulation of CD31/PECAMs in MCF-7, MDA-MB-231 cells and mammary tumors from MNU-induced rats. MH therapy has been shown to be significantly able to lower the serum leptin level and to be beneficial against the initiation of tumor development in SD rats for up to 12 weeks. Molecular modeling study revealed that MH has antagonized the effectiveness of several types of estrogen those bind to the ER alpha and has comparable binding efficacy to TAM.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer
    Zheng, Yang
    Zhang, Zeyuan
    Li, Dan
    Huang, Rong
    Ning, Shipeng
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (05):
  • [22] Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells
    Guarducci, C.
    Nardone, A.
    Feiglin, A.
    Migliaccio, I.
    Malorni, L.
    Bonechi, M.
    Benelli, M.
    Di Leo, A.
    Hodgson, G.
    Shapiro, G.
    Brown, M.
    Jeselsohn, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [23] Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
    Dean, Jeffry L.
    McClendon, A. Kathleen
    Hickey, Theresa E.
    Butler, Lisa M.
    Tilley, Wayne D.
    Witkiewicz, Agnieszka K.
    Knudsen, Erik S.
    CELL CYCLE, 2012, 11 (14) : 2756 - 2761
  • [24] Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors
    Lipton, N. J.
    Jesin, J.
    Warner, E.
    Cao, X.
    Kiss, A.
    Desautels, D.
    Jerzak, K. J.
    CURRENT ONCOLOGY, 2020, 27 (03) : 127 - 134
  • [25] Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer.
    Liu, Renyan
    Pantelidou, Constantia
    Jadhav, Heta
    Shapiro, Geoffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer
    Papadimitriou, Marios C.
    Pazaiti, Anastasia
    Iliakopoulos, Konstantinos
    Markouli, Mariam
    Michalaki, Vasiliki
    Papadimitriou, Christos A.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2022, 1869 (12):
  • [27] Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016)
    Herrera-Abreu, Maria Teresa
    Palafox, Marta
    Asghar, Uzma
    Rivas, Martin A.
    Cutts, Rosalind J.
    Garcia-Murillas, Isaac
    Pearson, Alex
    Guzman, Marta
    Rodriguez, Olga
    Grueso, Judit
    Bellet, Meritxell
    Cortes, Javier
    Elliott, Richard
    Pancholi, Sunil
    Lord, Christopher J.
    Baselga, Jose
    Dowsett, Mitch
    Martin, Lesley-Ann
    Turner, Nicholas C.
    Serra, Violeta
    CANCER RESEARCH, 2016, 76 (19) : 5907 - 5907
  • [28] RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes
    Pesch, Andrea M.
    Hirsh, Nicole H.
    Michmerhuizen, Anna R.
    Jungles, Kassidy M.
    Wilder-Romans, Kari
    Chandler, Benjamin C.
    Liu, Meilan
    Lerner, Lynn M.
    Nino, Charles A.
    Ward, Connor
    Cobain, Erin F.
    Lawrence, Theodore S.
    Pierce, Lori J.
    Rae, James M.
    Speers, Corey W.
    JCI INSIGHT, 2022, 7 (03)
  • [29] Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells
    Caroland, Kailey
    Shi, Changyou
    Lo, Hui-Wen
    Lin, Jiayuh
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long term growth inhibition in estrogen receptor positive breast cancer
    Oelmann, Elisabeth
    Michaloglou, Chrysiis
    Crafter, Claire
    Siersbaek, Rasmus
    Delpuech, Oona
    Curven, Jon
    Carnevalli, Larissa
    Staniszweska, Anna
    Polanska, Urszula
    Cheraghchi-Bashi, Azadeh
    Lawson, Mandy
    Chernukhin, Igor
    McEwen, Robert
    Carroll, Jason
    Cosulich, Sabina
    CANCER RESEARCH, 2018, 78 (04)